Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
Open Access
- 15 April 2025
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 14 (8) , e70890
Abstract
Backgrounds: Mitoxantrone hydrochloride liposome (Lipo‐MIT) has shown clinical benefits in various tumors. However, there is no prospective study evaluating its effectiveness and safety in relapsed/refractory multiple myeloma (RRMM). A phase I trial of bortezomib, Lipo‐MIT, and dexamethasone (VMitD) with the primary endpoints being safety and efficacy was performed.Methods: Twenty subjects were enrolled this study, and the dose of Lipo‐MIT was designed to be 12, 16, and 20 mg/m2 at Day 1 combined with bortezomib and dexamethasone.Results: The most common grade 3/4 non‐hematologic adverse event was pneumonia (20%). The most frequently observed grade 3/4 hematologic toxicity included thrombocytopenia (70%), neutropenia (55%), lymphopenia (30%), and anemia (10%). Fifteen subjects received at least one efficacy evaluation, including 60% (9/15) with a very good partial response (VGPR) or better, resulting in an overall response rate (ORR) of 86.7% (13/15).Conclusions: This is the first report about the novel triplet regimen VMitD, including Lipo‐MIT for RRMM, which was well tolerated and demonstrated efficacy. Further studies are required to assess the outcomes more accurately and to evaluate its effectiveness in comparison to other salvage regimens containing proteasome inhibitors and anthracyclines.Trial Registration: ClinicalTrials.gov identifier: NCT05052970Keywords
Funding Information
- National Natural Science Foundation of China (82100169)
This publication has 13 references indexed in Scilit:
- [Clinical Analysis of Mitoxantrone Liposome in the Treatment of Children with High-Risk Acute Myeloid Leukemia].2024
- Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myelomaBlood, 2019
- A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaClinical Cancer Research, 2019
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyondLeukemia, 2017
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Mitoxantrone, More than Just Another Topoisomerase II PoisonMedicinal Research Reviews, 2015
- Bortezomib‐containing induction regimens in transplant‐eligible myeloma patientsCancer, 2013
- Proteasome inhibitors in the treatment of multiple myelomaLeukemia, 2009
- Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to ProgressionJournal of Clinical Oncology, 2007
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003